Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Garmin Ltd. (GRMN) Price & Performance

Charles River Laboratories Intl. IncTrade
Garmin Ltd.Trade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Garmin Ltd. — how do they compare? Charles River Laboratories Intl. Inc trades at $286.75 (market cap $13.46B), while Garmin Ltd. trades at $310.47 (market cap $59.72B). The key difference: Garmin Ltd. is far larger — about 4.4× Charles River Laboratories Intl. Inc's market cap, and Garmin Ltd. pays a 1.36% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLGRMN
Market Cap
$13.46B$59.72B
Sector
HealthTechnology
52-Week High
$282.00$313.16
52-Week Low
$145.57$187.10
Enterprise Value
$16.30B$57.23B
Dividend Yield
1.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Garmin Ltd.

Garmin (GRMN) trades at $310.22, down 0.94% on the day, yet maintains a bullish technical trend with strong moving averages and support near $308. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 estimate, driven by 11% revenue growth. Profitability remains high, with a net margin of 24.47% and ROE of 21.89%, though valuation multiples like P/E of 31.96 appear elevated. Recent news highlights surging fitness segment demand and a raised 2026 outlook.

Garmin's outlook is supported by consistent earnings outperformance and growth in wearable technology, but risks include rich valuations and potential sales deceleration. Analyst consensus is a $318.67 price target with a Hold-heavy rating, suggesting cautious optimism amid near-term strength. The stock's proximity to its 52-week high warrants monitoring for sustainability of momentum.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Garmin Ltd.

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Read more on GRMN